FIELD: medicine.;SUBSTANCE: invention refers to medicine, particularly to pharmacology, and concerns development of the new antiaggregant. For this purpose Tropoxin (hydrochloride 3-(3,4,5-trioxybenzoyl-oxyimino)-8-methyl-8-azabicyclo[3,2,1]octane) commonly used as antimigraine agent.;EFFECT:...
网络凝集抑制作用 网络释义 1. 凝集抑制作用 专业词汇在线翻... ... 抗肾上腺药 antiadrenergic drugs凝集抑制作用antiaggregant activity抗凝集药 antiaggregating agent ... www.juyy.net|基于 1 个网页
antiaggregant activityantioxidant activity8-Bromo-1- iso -butyl-3-methyl-7-(thietanyl-3)xanthine ( II ) was synthesized by alkylation of 8-bromo-3-methyl-7-(thietanyl-3)xanthine ( I ) with isobutyl bromide. Nucleophilic substitution of II with thioglycolic acid gave 2{[1- iso -butyl-...
peptideThe structural features of Arg-Gly-Asp-related sequences have been investigated by 1H and 13C NMR. Two linear peptides which inhibit platelet aggregation with a high efficiency have been studied: D-Arg-Gly-Asp-Trp and L-Arg-Gly-Asp-Trp. Analysis of pH titration effects, amide proton...
Synthesis and antiaggregant and hypotensive activity of benzo-annelated azabicyclo[m.n.0]alkanesSynthesis and antiaggregant and hypotensive activity of benzo-annelated azabicyclo[m.n.0]alkanesisoquinolinesveratrolenitrilesoxiranesmulticomponent reactionsaggregation of erythrocytesThree...
ANTIAGGREGANT THERAPY OVERCOMES LIMITSAntiaggregant therapy overcomes limits.doi:10.1234/1819-6446-2009-5-93-95I. AndreevaИ. Андреева
platelet antiaggregant answers are found in the Taber's Medical Dictionary powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
[Anticoagulant and antiaggregant agents in patients with peripheral arterial occlusive disease.]Peripheral vascular occlusive disease (PAOD) is frequently seen in patients suffering from coronary heart or cerebrovascular disease and is, ... Dörffler-Melly,Schmidli,Mahler - 《Therapeutische Umschau》 被...
Table E2. Overview of concomitant use of antiaggregant and anticoagulant medication by patients in both cohorts Concomitant use of medicationPatients “AVR” cohort (n = 333)Patients “NVE” cohort (n = 137) Aspirin and VKA 14 (4.20%) 0 (0.0%) Aspirin and NOAC 29 (8.71%) 0 (0.0%) ...
[A clinico-morphological analysis of the efficacy of therapy in chronic glomerulonephritis using prednisone, a cytostatic, an anticoagulant and an antiaggregant] Four-component therapy (chlorbutin 0.2 mg, prednisone [correction of prednisolone] 60 mg, curantyl 400 mg/day per os, i.v. heparin 10...